Targeting Histone Deacetylase 8 as a Therapeutic Approach to Cancer and Neurodegenerative Diseases
Open accessThe DOI matches its Crossref record; 127 of the 127 references it cites were found in a registry or an index.
Abstract
Histone deacetylase 8 (HDAC8), a unique class I zinc-dependent HDAC, is an emerging target in cancer and other diseases. Its substrate repertoire extends beyond histones to many nonhistone proteins. Besides being a deacetylase, HDAC8 also mediates signaling via scaffolding functions. Aberrant expression or deregulated interactions with transcription factors are critical in HDAC8-dependent cancers. Many potent HDAC8-selective inhibitors with cellular activity and anticancer effects have been reported. We present HDAC8 as a druggable target and discuss inhibitors of different chemical scaffolds with cellular effects. Furthermore, we review HDAC8 activators that revert activity of mutant enzymes. Isotype-selective HDAC8 targeting in patients with HDAC8-relevant cancers is challenging, however, is promising to avoid adverse side effects as observed with pan-HDAC inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2 Histone deacetylase 8 expression in normal and tumor cells. R2 MegaSampler [66] with HDAC8 probe 223345_at. (A) HDAC8 expression of normal B cells (N1-2, blue), leukocytes (N3, blue) and expression in AML (1-8, green) and ALL (1-5, orange). (B) Normal (blue) colon (N1) expression compared with expression in colon cancer (T Colon 1-15, red). (C) Normal neural crest (N1, blue) expression compared with expression in neuroblastoma (1-4). (D) Normal neural crest (N1, blue) expression compared with expression in neuroblastoma INSS stage 4 and stage 4s samples of the Versteeg (1), Delattre (2), Hiyama (3) and Latowska (4) cohort. ALL: Acute lymphocytic leukemia; AML: Acute myeloid leukemia; HDAC8: Histone deacetylase 8.](https://figures.cochat.ai/paper-figures/e4cf4484a2ed428fa009973f11b9c76a/targeting-histone-deacetylase-8-as-a-therapeutic-approach-to-cancer-and-figure-2.png)







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“an HDAC isozyme that has been shown to be overexpressed in several cancers 19-21”
From Characterization of Histone Deacetylase 8 (HDAC8) Selective Inhibition Reveals Specific Active Site Structural and Functional Determinants (2018) · cites this paper as [19]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Chao, M., Chu, P., Chuang, H.-C., Shen, F.-H., Chou, C.-C., Hsu, E., Himmel, L. E., Huang, H.-L., Tu, H., Kulp, S. K., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6427 · Cited by 32
RetractedWang, Y., Xu, P., Yao, J., Yang, R., Shi, Z., Zhu, X., Feng, X., & Gao, S. (2015) · Targeted Oncology · doi:10.1007/s11523-015-0390-9 · Cited by 18
RetractedLysine acetylation targets protein complexes and co-regulates major cellular functions
Choudhary, C., Kumar, C., Gnad, F., Nielsen, M. L., Rehman, M., Walther, T. C., Olsen, J. V., & Mann, M. (2009) · Science · doi:10.1126/science.1175371 · Cited by 4,040
Haberland, M., Montgomery, R. L., & Olson, E. N. (2009) · Nature Reviews Genetics · doi:10.1038/nrg2485 · Cited by 2,526
Erasers of Histone Acetylation: The Histone Deacetylase Enzymes
Seto, E., & Yoshida, M. (2014) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a018713 · Cited by 1,989
Acetylation and deacetylation of non-histone proteins
Glozak, M. A., Sengupta, N., Zhang, X., & Seto, E. (2005) · Gene · doi:10.1016/j.gene.2005.09.010 · Cited by 1,584
Gregoretti, I., Lee, Y.-M., & Goodson, H. V. (2004) · Journal of Molecular Biology · doi:10.1016/j.jmb.2004.02.006 · Cited by 1,456
HDAC family: What are the cancer relevant targets?
Witt, O., Deubzer, H. E., Milde, T., & Oehme, I. (2009) · Cancer Letters · doi:10.1016/j.canlet.2008.08.016 · Cited by 1,069
Self-citationKelly, W. K., O'Connor, O. A., Krug, L. M., Chiao, J. H., Heaney, M., Curley, T., MacGregore-Cortelli, B., Tong, W., Secrist, J. P., Schwartz, L., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.14.167 · Cited by 905
Structural Snapshots of Human HDAC8 Provide Insights into the Class I Histone Deacetylases
Somoza, J. R., Skene, R. J., Katz, B. A., Mol, C., Ho, J. D., Jennings, A. J., Luong, C., Arvai, A., Buggy, J. J., Chi, E., et al. (2004) · Structure · doi:10.1016/j.str.2004.04.012 · Cited by 710
Cited by
Indole in the target-based design of anticancer agents: A versatile scaffold with diverse mechanisms
Dadashpour, S., & Emami, S. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.02.065 · Cited by 343
Dual-Target Inhibitors Based on HDACs: Novel Antitumor Agents for Cancer Therapy
Liu, T., Wan, Y., Xiao, Y., Xia, C., & Duan, G. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00491 · Cited by 186
Next-generation of selective histone deacetylase inhibitors
Yang, F., Zhao, N., Ge, D., & Chen, Y. (2019) · RSC Advances · doi:10.1039/c9ra02985k · Cited by 155
Marek, M., Shaik, T. B., Heimburg, T., Chakrabarti, A., Lancelot, J., Ramos-Morales, E., Da Veiga, C., Kalinin, D., Melesina, J., Robaa, D., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01087 · Cited by 122
Self-citationStrategies To Design Selective Histone Deacetylase Inhibitors
Melesina, J., Simoben, C. V., Praetorius, L., Bülbül, E. F., Robaa, D., & Sippl, W. (2021) · ChemMedChem · doi:10.1002/cmdc.202000934 · Cited by 118
Self-citation
Metadata
- Authors
- Chakrabarti, A., Melesina, J., Kolbinger, F. R., Oehme, I., Senger, J., Witt, O., Sippl, W., & Jung, M.
- Affiliations
- University of Freiburg (DE)
- Martin Luther University Halle-Wittenberg (DE)
- German Cancer Research Center (DE)
- Venue
- Future Medicinal Chemistry
- Publisher
- Informa UK Limited
- Published
- 2016-08-30
- Volume
- 8
- Issue
- 13
- Pages
- 1609-1634
- ISSN
- 1756-8919 (ISSN-L)
- 1756-8927
- OpenAlex
- W2510695850
- Cited by
- 111
- References
- 127
- Citations by year
- 2026: 8 · 2025: 9 · 2024: 12 · 2023: 8 · 2022: 14 · 2021: 8 · 2020: 15 · 2019: 14 · 2018: 14 · 2017: 9
- FWCI
- 1.21
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Future Medicinal Chemistry (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- FreiDok plus (Universitätsbibliothek Freiburg) (submittedVersion)
- Funders
- H.W. & J Hector foundation
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Enzyme function and inhibition
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Keywords
- HDAC8, HDAC8 inhibitors, class I HDACs, transcription factor interaction, cancer therapy, neurodegenerative diseases
- MeSH terms
- Antineoplastic Agents, Histone Deacetylases, Humans, Neoplasms, Repressor Proteins, Neuroprotective Agents, Neurodegenerative Diseases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting Histone Deacetylase 8 as a Therapeutic Approach to Cancer and Neurodegenerative Diseases. https://app.cochat.ai/papers/10.4155/fmc-2016-0117
- The paper
- Chakrabarti, A., Melesina, J., Kolbinger, F. R., Oehme, I., Senger, J., Witt, O., Sippl, W., & Jung, M. (2016). Targeting Histone Deacetylase 8 as a Therapeutic Approach to Cancer and Neurodegenerative Diseases. Future Medicinal Chemistry. https://doi.org/10.4155/fmc-2016-0117
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.